On Thursday, Cathie Wood-led Ark Invest made significant trades involving Tempus AI Inc and GitLab Inc. These trades reflect Ark’s strategic positioning in the tech and AI sectors, following recent earnings reports from both companies.
Ark Invest’s ARK Innovation ETF acquired 225,833 shares of Tempus AI, while ARK Genomic Revolution ETF purchased 44,969 shares. The transactions were valued at $13.23 million. For the day, Tempus AI shares ended 7.9% lower at $48.86.
These trades come after Tempus AI’s recent quarterly earnings report, which showed a revenue miss but an earnings-per-share beat. The company reported fourth-quarter revenue of $200.68 million, falling short of the $203.12 million estimate. However, its adjusted loss of 18 cents per share was better than the anticipated 20-cent loss.
Despite the mixed results, Tempus AI provided strong guidance. Analysts have varied opinions on Tempus AI, with some expressing bullish sentiments while others remaining cautious.
On the same day, Ark Invest’s ARKK and ARK Next Generation Internet ETF collectively purchased 86,906 shares of GitLab. This trade was valued at $5.06 million based on Thursday’s closing price of $58.25.
This move follows GitLab’s impressive fourth-quarter earnings report, which exceeded expectations. GitLab reported earnings of 33 cents per share, surpassing the consensus estimate of 23 cents. Additionally, its revenue of $211.43 million beat the expected $206.12 million.
Purchased Ibotta Inc. (IBTA) stock through ARKK and ARKF
Purchased Recursion Pharmaceuticals Inc. (RXRX) shares through ARKG.
Sold shares of Uipath Inc. (PATH) via ARKK and Draftkings Inc. (DKNG) through ARKW.
ARKG sold Repare Therapeutics Inc. (RPTX) and Exact Sciences Corp. (EXAS) stock
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.